CN118317946A - 用于制备巴瑞替尼的方法和中间体 - Google Patents

用于制备巴瑞替尼的方法和中间体 Download PDF

Info

Publication number
CN118317946A
CN118317946A CN202280059305.2A CN202280059305A CN118317946A CN 118317946 A CN118317946 A CN 118317946A CN 202280059305 A CN202280059305 A CN 202280059305A CN 118317946 A CN118317946 A CN 118317946A
Authority
CN
China
Prior art keywords
formula
compound
salt
reaction
prepared
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280059305.2A
Other languages
English (en)
Chinese (zh)
Inventor
J·周
S·陈
Z·贾
P·刘
D·梅洛尼
Y·潘
N·苏
M·夏
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Incyte Corp
Original Assignee
Incyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Corp filed Critical Incyte Corp
Publication of CN118317946A publication Critical patent/CN118317946A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN202280059305.2A 2021-07-12 2022-07-11 用于制备巴瑞替尼的方法和中间体 Pending CN118317946A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163220752P 2021-07-12 2021-07-12
US63/220,752 2021-07-12
PCT/US2022/073599 WO2023288197A1 (en) 2021-07-12 2022-07-11 Process and intermediates for preparing baricitinib

Publications (1)

Publication Number Publication Date
CN118317946A true CN118317946A (zh) 2024-07-09

Family

ID=82748410

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280059305.2A Pending CN118317946A (zh) 2021-07-12 2022-07-11 用于制备巴瑞替尼的方法和中间体

Country Status (6)

Country Link
US (2) US12071439B2 (cg-RX-API-DMAC10.html)
EP (1) EP4370504A1 (cg-RX-API-DMAC10.html)
JP (1) JP7880946B2 (cg-RX-API-DMAC10.html)
CN (1) CN118317946A (cg-RX-API-DMAC10.html)
CA (1) CA3226714A1 (cg-RX-API-DMAC10.html)
WO (1) WO2023288197A1 (cg-RX-API-DMAC10.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117903032A (zh) * 2022-10-12 2024-04-19 重庆博腾制药科技股份有限公司 一种巴瑞替尼中间体的制备方法及制备巴瑞替尼的方法

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL300555A (en) 2020-08-18 2023-04-01 Incyte Corp Process and intermediates for preparing a JAK inhibitor
CA3192055A1 (en) 2020-08-18 2022-02-24 Incyte Corporation Process and intermediates for preparing a jak1 inhibitor
CN117567343A (zh) * 2023-11-23 2024-02-20 瑞阳制药股份有限公司 安全高效制备巴瑞替尼关键中间体的方法
CN121135621A (zh) * 2024-06-07 2025-12-16 上海长森药业有限公司 一种jak抑制剂的制备方法及其中间体

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB812366A (en) 1955-08-18 1959-04-22 Wellcome Found Improvements in and relating to derivatives of pyrimidine and the preparation thereof
US4264609A (en) * 1980-02-26 1981-04-28 Sterling Drug Inc. N-[3-Dimethylamino-2-(4-pyridinyl)-2-propenylidene]-N-methylmethaniminium chloride hydrochloride, its use in preparing 5-(cyano or carbamyl)-[3,4'-bipyridin]-6(1H)-one and its use as a cardiotonic
US5102904A (en) 1989-12-08 1992-04-07 American Cyanamid Company N-oxygenated arylpyrrole insecticidal, acaricidal and nematicidal agents and use thereas
WO2004021979A2 (en) 2002-09-06 2004-03-18 Smithkline Beecham Corporation PYRROLO[2, 3-d]PYRIMIDINE-4-YL AND PURIN-6-YL UREA COMPOUNDS
JP4842929B2 (ja) 2004-05-27 2011-12-21 ファイザー・プロダクツ・インク 癌治療に有用なピロロピリミジン誘導体
AR054416A1 (es) 2004-12-22 2007-06-27 Incyte Corp Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas.
WO2007012953A2 (en) 2005-07-29 2007-02-01 Pfizer Products Inc. Pyrrolo[2,3-d]pyrimidine derivatives; their intermediates and synthesis
HUE028588T2 (hu) 2005-12-13 2016-12-28 Incyte Holdings Corp Heteroaril-szubsztituált pirrolo[2,3-b]piridinek és pirrolo[2,3-b]pirimidinek mint Janus-kináz inhibitorok
HRP20120786T1 (hr) 2006-02-02 2012-11-30 Millennium Pharmaceuticals, Inc. Inhibitori aktivirajuä†eg enzima e1
CL2008001709A1 (es) 2007-06-13 2008-11-03 Incyte Corp Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
EP2740731B1 (en) 2007-06-13 2016-03-23 Incyte Holdings Corporation Crystalline salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
BRPI0815042A2 (pt) 2007-08-01 2015-02-10 Pfizer Compostos de pirazol
EA020777B1 (ru) 2007-11-16 2015-01-30 Инсайт Корпорейшн 4-пиразолил-n-арилпиримидин-2-амины, 4-пиразолил-n-пиразолилпиримидин-2-амины и 4-пиразолил-n-пиридилпиримидин-2-амины в качестве ингибиторов киназ janus
MY165582A (en) 2008-03-11 2018-04-05 Incyte Holdings Corp Azetidine and cyclobutane derivatives as jak inhibitors
CL2009001884A1 (es) 2008-10-02 2010-05-14 Incyte Holdings Corp Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco.
WO2010083283A2 (en) 2009-01-15 2010-07-22 Incyte Corporation Processes for preparing jak inhibitors and related intermediate compounds
CA2756250A1 (en) 2009-04-10 2010-10-14 Pfizer Inc. 4,5-dihydro-1h-pyrazole compounds and their pharmaceutical uses
BRPI1012108B8 (pt) 2009-05-22 2021-05-25 Incyte Corp composto 3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]octa no- ou heptano-nitrila, sua composição, seus usos e processo para preparar um sal de ácido fosfórico
NZ596479A (en) 2009-05-22 2014-01-31 Incyte Corp N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
TW201113285A (en) 2009-09-01 2011-04-16 Incyte Corp Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
EA021478B1 (ru) 2009-10-09 2015-06-30 Инсайт Корпорейшн ГИДРОКСИЛЬНЫЕ, КЕТО И ГЛЮКУРОНИДНЫЕ ПРОИЗВОДНЫЕ 3-(4-(7Н-ПИРРОЛО[2,3-d]ПИРИМИДИН-4-ИЛ)-1Н-ПИРАЗОЛ-1-ИЛ)-3-ЦИКЛОПЕНТИЛПРОПАННИТРИЛА
CN102573478B (zh) 2009-10-12 2015-12-16 拜尔农作物科学股份公司 作为杀虫剂的1-(吡啶-3-基)-吡唑和1-(嘧啶-5-基)-吡唑
JP2013510166A (ja) 2009-11-06 2013-03-21 プレキシコン インコーポレーテッド キナーゼ調節のための化合物、方法およびその適用
EP2501236B1 (en) 2009-11-18 2017-03-29 Plexxikon Inc. N-[2-fluoro-3-(4-amino-7H-pyrrolo[2,3-d]pyrimidine-5-carbonyl)-phenyl]-4-benzenesulfonamide derivatives as Raf protein kinase modulators for the treatment of cancer
US20110207754A1 (en) 2010-02-18 2011-08-25 Incyte Corporation Cyclobutane and methylcyclobutane derivatives as janus kinase inhibitors
CA2792508C (en) 2010-03-10 2018-01-16 Incyte Corporation Piperidin-4-yl azetidine derivatives as jak1 inhibitors
TWI510487B (zh) 2010-04-21 2015-12-01 Plexxikon Inc 用於激酶調節的化合物和方法及其適應症
EA202091303A3 (ru) 2010-05-21 2021-05-31 Инсайт Холдингс Корпорейшн Композиция ингибитора jak для местного применения
CA2818542A1 (en) 2010-11-19 2012-05-24 Incyte Corporation Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
ES2536415T3 (es) 2010-11-19 2015-05-25 Incyte Corporation Pirrolopiridinas y pirrolopirimidinas sustituidas heterocíclicas como inhibidores de JAK
PH12013501557A1 (en) 2011-02-08 2019-06-03 Pfizer Glucagon receptor modulator
US8691807B2 (en) 2011-06-20 2014-04-08 Incyte Corporation Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors
BR112014002472A2 (pt) 2011-08-12 2017-04-11 Nissan Chemical Ind Ltd "compostos heterocíclicos tricíclicos, seu uso, agente terapêutico para reumatismo articular e medicamento"
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為jak抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
TW201406761A (zh) 2012-05-18 2014-02-16 Incyte Corp 做爲jak抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物
KR102242077B1 (ko) 2012-11-15 2021-04-20 인사이트 홀딩스 코포레이션 룩솔리티니브의 서방성 제형
EP3489239B1 (en) 2013-03-06 2021-09-15 Incyte Holdings Corporation Processes and intermediates for making a jak inhibitor
CR20190156A (es) 2013-05-17 2019-05-16 Incyte Corp Derivados de bipirazol como inhibidores jak
MX376856B (es) 2013-08-07 2025-03-07 Incyte Holdings Corp Formas de dosificacion de liberacion prolongada para un inhibidor de jak 1 (cinasa de janus 1).
SG11201609016VA (en) 2014-04-30 2016-11-29 Incyte Corp Processes of preparing a jak1 inhibitor and new forms thereto
ES2874537T3 (es) 2014-08-21 2021-11-05 Ratiopharm Gmbh Sal oxalato de ruxolitinib
WO2016026975A1 (en) 2014-08-21 2016-02-25 Ratiopharm Gmbh Salt of (r)-3-(4-(7h-pyrrolo [2,3-d] pyrimidin-4-yl)-lh-pyrazol-l-yl)-3-cyclopentylpropanenitrile with benzenesulfonic acid
WO2016035014A1 (en) 2014-09-01 2016-03-10 Sun Pharmaceutical Industries Limited Processes for the preparation of ruxolitinib phosphate
WO2016063294A2 (en) 2014-10-20 2016-04-28 Msn Laboratories Private Limited Process for the preparation of (r)-3-(4-(7h-pyrrolo[2,3-d], pyrimidin-4-yl)-1 h-pyrazol-1-yl)-3-cyclopentylpropanenitrile phosphate and its polymorphs thereof
EA031895B1 (ru) 2015-02-24 2019-03-29 Пфайзер Инк. Замещенные нуклеозидные производные, полезные в качестве агентов против рака
CA2928286A1 (en) 2015-04-28 2016-10-28 Signa S.A. De C.V. Solid form of ruxolitinib phosphate
AR104918A1 (es) 2015-06-19 2017-08-23 Lilly Co Eli Procesos e intermediarios para la preparación de {1-(etilsulfonil)-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]azetidin-3-il}acetonitrilo
CN106397443A (zh) 2015-07-17 2017-02-15 浙江九洲药业股份有限公司 一种吡咯嘧啶类衍生物中间体的制备方法
CZ2015575A3 (cs) 2015-08-26 2017-03-08 Zentiva, K.S. Soli 5-fluoro-3-fenyl-2-[(1S)-1-(9H-purin-6-ylamino)propyl]quinazolin-4-onu a jejich příprava
ES2954596T3 (es) 2015-12-23 2023-11-23 Univ British Columbia Profármacos unidos a lípidos
ES2882118T3 (es) 2015-12-31 2021-12-01 Chia Tai Tianqing Pharmaceutical Group Co Ltd Procedimiento de síntesis de ruxolitinib
CZ201629A3 (cs) 2016-01-22 2017-08-02 Zentiva, K.S. Krystalické modifikace solí (3R)-3-cyklopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propannitrilu a způsoby jejich přípravy
CN107513069A (zh) 2016-06-16 2017-12-26 正大天晴药业集团股份有限公司 手性吡咯并嘧啶化合物的制备方法
IN201641026603A (cg-RX-API-DMAC10.html) 2016-08-04 2018-02-09
CN107722012B (zh) 2016-08-11 2020-05-29 斯福瑞(南通)制药有限公司 制备4-氯-7H-吡咯并[2,3-d]嘧啶的方法
CN107759601B (zh) 2016-08-23 2020-09-11 苏州旺山旺水生物医药有限公司 一种jak抑制剂及其盐的制备方法
CN107759623B (zh) 2016-08-23 2020-08-14 苏州旺山旺水生物医药有限公司 Jak抑制剂的中间体及其制备方法
EP3515909A1 (en) 2016-09-23 2019-07-31 Cellipse Lim kinase inhibitors, pharmaceutical composition and method of use in limk-mediated diseases
CN109651424B (zh) 2017-10-11 2021-01-22 新发药业有限公司 一种7-保护基-4-(1-氢-吡唑-4-基)吡咯[2,3-d]嘧啶的合成方法
US10766900B2 (en) 2017-12-29 2020-09-08 Formosa Laboratories, Inc. Baricitinib intermediate, method for forming Baricitinib intermediate, and method for preparing Baricitinib or pharmaceutically acceptable salt thereof
MD3746429T2 (ro) 2018-01-30 2022-08-31 Incyte Corp Procedee pentru prepararea de (1-(3-fluoro-2-(trifluorometil)izonicotinil)piperidin-4-onă)
CN112041303A (zh) 2018-05-21 2020-12-04 Pi工业有限公司 制备取代的杂环化合物的方法
EP3921318A1 (en) 2019-02-06 2021-12-15 Concert Pharmaceuticals Inc. Process for preparing enantiomerically enriched jak inhibitors
CN110724145A (zh) 2019-11-01 2020-01-24 廖文杰 一种医药中间体4-氯吡咯并嘧啶的合成方法
CA3192055A1 (en) 2020-08-18 2022-02-24 Incyte Corporation Process and intermediates for preparing a jak1 inhibitor
IL300555A (en) 2020-08-18 2023-04-01 Incyte Corp Process and intermediates for preparing a JAK inhibitor
CN113480546A (zh) 2021-07-30 2021-10-08 江苏君若药业有限公司 巴瑞克替尼及其衍生物的制备

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117903032A (zh) * 2022-10-12 2024-04-19 重庆博腾制药科技股份有限公司 一种巴瑞替尼中间体的制备方法及制备巴瑞替尼的方法

Also Published As

Publication number Publication date
WO2023288197A1 (en) 2023-01-19
JP2024526762A (ja) 2024-07-19
US12071439B2 (en) 2024-08-27
EP4370504A1 (en) 2024-05-22
US20230059389A1 (en) 2023-02-23
JP7880946B2 (ja) 2026-06-26
US20240368171A1 (en) 2024-11-07
CA3226714A1 (en) 2023-01-19

Similar Documents

Publication Publication Date Title
TWI904215B (zh) 製備jak1抑制劑之方法及中間體
TWI913303B (zh) 製備jak抑制劑之方法及中間體
US12071439B2 (en) Process and intermediates for preparing a JAK inhibitor
EP1602646A1 (en) Processes for producing cyclic benzamidine derivative
CN116761792A (zh) 用于制备jak抑制剂的方法和中间体
CN115989226B (zh) 制备jak抑制剂的方法和中间体
JP5711669B2 (ja) スピロケタール誘導体の製造方法
EA049332B1 (ru) Способ и промежуточные соединения для получения ингибитора jak1
BR122025013614A2 (pt) Processo para preparar um inibidor de jak, seus intermediários e formas cristalinas
CN117377660A (zh) 用于苯并氧氮杂䓬恶唑烷酮化合物的制备的方法
BR122025024131A2 (pt) Processo para preparar um inibidor de jak, seus intermediários e formas cristalinas
HK1215809B (en) Method for producing tricyclic compound, and tricyclic compound capable of being produced by said production method
HK1215809A1 (zh) 制备三环化合物的方法以及可通过所述制备方法制备的三环化合物
CN121135621A (zh) 一种jak抑制剂的制备方法及其中间体

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination